17 January 2025
17 January 2025
Potential antitrust deregulation could foster a more favourable environment for larger M&A deals, though skepticism remains.
Key differences occurred in neurological indications courtesy of Kisunla and Cobenfy.
At the JP Morgan Conference 2025, CEO Chen said the potential of the Biosecure Act passing has had only a minimal chilling effect on clients.
The radiopharmaceutical developer expanded its reach, acquiring R&D, isotope production, manufacturing, and distribution.
NICE’s positive final guidance for Agamree follows confirmation that no appeals were submitted against its positive December 2024 draft guidance.
Six out of 31 total new small molecules approved by the FDA in 2024 were produced by Wuxi, said the company's co-CEO.
AstraZeneca’s Fasenra, an IL-5-targeting monoclonal antibody already approved for asthma, represents a promising contender for market share in COPD.
Meridian’s DuoDote autoinjectors will be manufactured at the Missouri-based facility of Meridian's parent company Kindeva Drug Delivery.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
